DALLAS, Jan. 25, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Hemispherx Biopharma Inc. (AMEX:HEB). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.investorsoup.com/lp/HEB
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup">www.twitter.com/investorsoup
Hemispherx Biopharma Inc. (HEB) is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's products include Ampligen and Alferon N and Injection.
Message Board Search for HEB: http://www.boardcentral.com/boards/HEB
In the report, the analyst notes:
"HEB net loss was approximately $2,435,000 for the three months ended September 30, 2009, was $980,000 or 29% less when compared to the same period in 2008. This decrease in loss for these three months was primarily due to the following expense elements:
- Production/Cost of Goods Sold decreased approximately $53,000 or 27%.
- Research and Development costs were down approximately $421,000 or 26%.
- General and Administrative expenses decreased approximately $511,000 or 31%.
"HEB stated that on January 14, 2010, the Company submitted reports of new preclinical data regarding Ampligen (Poly I: Poly C12U), an experimental therapeutic being developed for potential treatment of Chronic Fatigue Syndrome ("CFS"), to the Food and Drug Administration ("FDA"). Hemispherx management believes these reports should be sufficient to address certain preclinical issues referenced in periodic reports filed by the Company with the Securities and Exchange Commission ("SEC"), including, most recently, the Company's Form 10-Q filed with the SEC on November 9, 2009, as well as in a Complete Response Letter from the FDA described in a December 1, 2009 press release."
To read the entire report visit: http://www.investorsoup.com/lp/HEB
See what investors say about HEB at penny stock forum
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit www.InvestorSoup.com/">http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.